Professor Colin Dayan
Prosiectau fel Prif Ymchwiliwr
- Reducing the impact of diabetic foot ulcers on patients and the health service: The REDUCE programme (01.10.2016 - 31.12.2017)
- Regulatory CD8 cells in type 1 diabetes (20.06.2011 - 14.08.2011)
- Safety and proof of principle study of ATX-GC-59 in male and female subjects with Graves' disease not currently treated with anti-thyroid therapy: An open label study with an upward titration over 5 dose levels administered by intradermal injection (01.08.2016 - 31.03.2020)
- Supplement to bridge existing ACC into collaborative ACC biomarker study. (01.10.2011 - 30.06.2012)
- T1D-Plus: a clinical trial platform for combined beta cell preservation therapy (01.09.2022 - 31.08.2026)
Prosiectau fel Cyd-Ymchwiliwr
- Development of urinary microRNAs as biomarkers for diabetic kidney disease (01.04.2013 - 31.07.2018)
- Identifying islet antigen specific lymphocytes by recruitment to intradermally injected autoantigens, using single cell RNA sequencing: a route to novel cell based therapies and immune monitoring (01.01.2021 - 31.03.2024)
- Microneedle technology to deliver peptide immunotherapy for type 1 diabetes (01.08.2011 - 31.08.2015)
- Neuropsychological testing in children aged 8-10 years in the controlled antenatal thyroid screening (CATS) study II (11.02.2013 - 31.12.2015)
- Peptide-HLA multimers as biomarkers of autoimmune disease (01.07.2012 - 31.07.2014)